1 October 2025

MedPal AI Plc

("MedPal AI" or the "Company")

Placing to raise £400,000

Further to its announcement today of the acquisition of certain assets from Universal Pharmacy Ltd (in administration) which can be viewed here News article | London Stock Exchange, MedPal AI (AIM: MPAL), the digital health platform, is pleased to announce that it has completed a placing of new ordinary shares (the "Placing Shares") to raise £400,000 for the Company (the "Placing"). The Placing Shares are to be issued at 8p per share (the "Issue Price"), which represents a discount of approximately 5.9 per cent. to the mid-market closing price of an Ordinary Share on 30 September 2025 (being the latest practicable date prior to this announcement).

The proceeds of the Placing and of a WRAP Retail Offer, to be launched shortly by the Company and announced separately, will be used to progress the Company's strategy with regard to the recently announced acquisition of assets from Universal Pharmacy Ltd (in administration), which will enable MedPal AI to establish itself in the rapidly growing GLP-1 agonist market for obesity treatment, including drugs such as semaglutide (eg. Ozempic and Mounjaro).

For the avoidance of doubt, the Placing is not part of the WRAP Retail Offer by the Company.

The Placing is conditional on the Placing Shares being admitted to trading on AIM ("Admission"). It is anticipated that Admission will become effective and that dealings in the Placing Shares will commence on AIM at 8.00 a.m. on 8 October 2025.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Further information on the Company can be found on its website at www.medpalplc.com

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors.